Evidence map›Paper›PMID 28969695›Full record

ArticleMolecular neurodegeneration2017

Together JUN and DDIT3 (CHOP) control retinal ganglion cell death after axonal injury.

Stephanie B Syc-Mazurek, Kimberly A Fernandes, Michael P Wilson, Peter Shrager, Richard T Libby

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. IL1A enhances TNF-induced retinal ganglion cell death.Frontiers in aging neuroscience · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. A lead role for a "secondary" axonal injury response.Neural regeneration research · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Stephanie B Syc-MazurekDepartment of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Box 314, 601 Elmwood Ave, Rochester, NY, 14642, USA.
Kimberly A FernandesDepartment of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Box 314, 601 Elmwood Ave, Rochester, NY, 14642, USA.
Michael P WilsonDepartment of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Box 314, 601 Elmwood Ave, Rochester, NY, 14642, USA.
Peter ShragerDepartment of Neuroscience, Rochester, USA.
Richard T LibbyDepartment of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Box 314, 601 Elmwood Ave, Rochester, NY, 14642, USA. richard_libby@urmc.rochester.edu.
University of Rochester · USUniversity of Rochester Medical Center · US

Funding

Cell Death Pathways in Glaucomatous NeurodegenerationR01EY018606 · NEI · UNIVERSITY OF ROCHESTER · PI JOHN, SIMON W, LIBBY, RICHARD T · 2008 to 2023
$5.8M
NEI NIH HHS R01 EY018606
6 · The paper itself

Abstract

backgroundOptic nerve injury is an important pathological component in neurodegenerative diseases such as traumatic optic neuropathies and glaucoma. The molecular signaling pathway(s) critical for retinal ganglion cell (RGC) death after axonal insult, however, is/are not fully defined. RGC death after axonal injury is known to occur by BAX-dependent apoptosis. Two transcription factors JUN (the canonical target of JNK) and DDIT3 (CHOP; a key mediator of the endoplasmic reticulum stress response) are known to be important apoptotic signaling molecules after axonal injury, including in RGCs. However, neither Jun nor Ddit3 deficiency provide complete protection to RGCs after injury. Since Jun and Ddit3 are important apoptotic signaling molecules, we sought to determine if their combined deficiency might provide additive protection to RGCs after axonal injury.

methodsTo determine if DDIT3 regulated the expression of JUN after an axonal insult, mice deficient for Ddit3 were examined after optic nerve crush (ONC). In order to critically test the importance of these genes in RGC death after axonal injury, RGC survival was assessed at multiple time-points after ONC (14, 35, 60, and 120 days after injury) in Jun, Ddit3, and combined Jun/Ddit3 deficient mice. Finally, to directly assess the role of JUN and DDIT3 in axonal degeneration, compound actions potentials were recorded from Jun, Ddit3, and Jun/Ddit3 deficient mice after ONC.

resultsSingle and combined deficiency of Jun and Ddit3 did not appear to alter gross retinal morphology. Ddit3 deficiency did not alter expression of JUN after axonal injury. Deletion of both Jun and Ddit3 provided significantly greater long-term protection to RGCs as compared to Jun or Ddit3 deficiency alone. Finally, despite the profound protection to RGC somas provided by the deficiency of Jun plus Ddit3, their combined loss did not lessen axonal degeneration.

conclusionsThese results suggest JUN and DDIT3 are independently regulated pro-death signaling molecules in RGCs and together account for the vast majority of apoptotic signaling in RGCs after axonal injury. Thus, JUN and DDIT3 may represent key molecular hubs that integrate upstream signaling events triggered by axonal injury with downstream transcriptional events that ultimately culminate in RGC apoptosis.

Indexed as

AnimalsApoptosisAxonsGenes, junMiceMice, Inbred C57BLMice, Mutant StrainsNerve CrushNerve DegenerationOptic Nerve InjuriesRetinal Ganglion CellsSignal TransductionTranscription Factor CHOPTranscription Factor CHOPAxonopathyEndoplasmic reticulum stressMitogen-activated protein kinaseNeurodegenerationRetinal ganglion cell

Identifiers

PMID28969695
PMCPMC5625643
OpenAlexW2762394431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.